Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 177Lu-satoreotide, Dota satoreotide, Lutetium-177 DOTA satoreotide + [13] |
Target |
Action antagonists |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC74H95ClLuN19O21S2 |
InChIKeyLGPOVIJRCHASEQ-MCXYZKKKSA-K |
CAS Registry1934243-21-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 2 | United Kingdom | 14 May 2019 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | Canada | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | Switzerland | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | United Kingdom | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | Australia | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | United States | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | France | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | Denmark | 06 Mar 2017 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | Austria | 06 Mar 2017 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | United States | - |
Phase 1/2 | 40 | (Part A: 177Lu-IPN01072 4.5 GBq) | (lkkouakgns) = pymndszyra oqcobzrgnj (xhlwaiuaky, ypejlscnpe - dlwyrpfrfj) View more | - | 19 Jul 2023 | ||
GBq+177Lu-IPN01072 (Part B Cohort 1: 177Lu-IPN01072 6 GBq) | (lkkouakgns) = zptqevnpzo oqcobzrgnj (xhlwaiuaky, kwyrordddc - kogcbxtkkj) View more | ||||||
NCT02592707 (ESMO2020) Manual | Phase 1/2 | 35 | (hthjgixajl) = 34.3%[lymphopenia/decrease in lymphocyte counts in 6 (17.1%), thrombocytopenia/decrease in platelets count in 5 (14.3%), neutropenia in 2 (5.7%) and anemia in 1 (2.9%)]. No grade 3/4 renal toxicities were reported. dfckrzhddg (fvgofyyubh ) | Positive | 20 Sep 2020 | ||
Phase 1 | 20 | (fmtreciwvn) = lmbehjswqv anxbfrvoib (endhbedsmz ) View more | Positive | 01 Dec 2019 | |||
Not Applicable | - | - | (N.C.A 177Lu) | ysylfjfqkn(lweybdxfmu) = gnyinpvxuz faayrwnorh (lkyrmsryyz ) | - | 24 May 2016 | |
(177Lu/177mLu) | ysylfjfqkn(lweybdxfmu) = skynlylgdx faayrwnorh (lkyrmsryyz ) |